Study S002693

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight, and Type 2 Diabetes Mellitus (VESPER-2)

ClinicalTrials.gov record

Registration

Registration: NCT06897202
Acronym: VESPER-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 133
Start: 2025-03-14
Primary completion: 2025-12-29
Lead sponsor: Pfizer
Conditions: Obesity in Diabetes; Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:MET097 Injection; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:C6491005

Registered primary outcomes

Percent change from baseline in body weight at Week 28 (Day 197) [Baseline (Week 0) through Week 28 (Day 197)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.